Rossmore Private Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$598K Sell
4,732
-50
-1% -$6.59K 0.05% 196
2026
Q1
$666K Buy
4,782
+600
+14% +$84K 0.06% 175
2025
Q4
$513K Buy
4,182
+200
+5% +$24.3K 0.05% 200
2025
Q3
$442K Hold
3,982
0.05% 194
2025
Q2
$441K Buy
+3,982
New +$424K 0.05% 188
2024
Q2
Sell
-5,686
Closed -$417K 232
2024
Q1
$417K Sell
5,686
-100
-2% -$7.69K 0.05% 184
2023
Q4
$469K Buy
5,786
+25
+0.4% +$1.95K 0.07% 162
2023
Q3
$432K Sell
5,761
-300
-5% -$23.1K 0.07% 163
2023
Q2
$467K Sell
6,061
-2,000
-25% -$160K 0.07% 157
2023
Q1
$669K Hold
8,061
0.1% 139
2022
Q4
$692K Buy
8,061
+332
+4% +$26.3K 0.11% 135
2022
Q3
$477K Hold
7,729
0.09% 151
2022
Q2
$478K Buy
7,729
+400
+5% +$24.8K 0.08% 156
2022
Q1
$436K Sell
7,329
-350
-5% -$22.4K 0.07% 165
2021
Q4
$558K Hold
7,679
0.09% 150
2021
Q3
$536K Sell
7,679
-1,000
-12% -$70.3K 0.09% 149
2021
Q2
$598K Hold
8,679
0.1% 146
2021
Q1
$561K Buy
8,679
+955
+12% +$61.6K 0.11% 144
2020
Q4
$450K Buy
7,724
+3,262
+73% +$197K 0.09% 150
2020
Q3
$282K Buy
4,462
+26
+0.6% +$1.8K 0.07% 160
2020
Q2
$341K Buy
+4,436
New +$340K 0.09% 129
2018
Q1
Sell
-900
Closed -$64.5K 226
2017
Q4
$64.5K Buy
+900
New +$68.3K 0.07% 149

Other funds holding GILD

Rossmore Private Capital's GILD Position: Q2 2026 in Review

Rossmore Private Capital reduced its Gilead Sciences (GILD) stake by 1% in Q2 2026, selling an estimated $6.59K and leaving 4,732 shares worth $598K. The position accounts for 0.05% of the portfolio, ranked #196.

Rossmore Private Capital first reported a position in GILD in Q4 2017 and has held it in 22 quarters since. The position peaked at $692K in Q4 2022. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Rossmore Private Capital held 4,732 shares of Gilead Sciences worth $598K as of Q2 2026.
  • Rossmore Private Capital sold 50 Gilead Sciences shares in Q2 2026, an estimated $6.59K.
  • Gilead Sciences made up 0.05% of Rossmore Private Capital's portfolio in Q2 2026, its #196 holding.
  • Rossmore Private Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 22 quarters since.
  • Rossmore Private Capital's Gilead Sciences position peaked at $692K in Q4 2022.
  • 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Rossmore Private Capital's 13F filing for Q2 2026, filed 31 Jul 2026.